Cargando…
Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909442/ https://www.ncbi.nlm.nih.gov/pubmed/31836017 http://dx.doi.org/10.1186/s13063-019-3940-0 |
| _version_ | 1783478939997437952 |
|---|---|
| author | de Jong, Wesley Aerts, Joeri Allard, Sabine Brander, Christian Buyze, Jozefien Florence, Eric van Gorp, Eric Vanham, Guido Leal, Lorna Mothe, Beatriz Thielemans, Kris Plana, Montse Garcia, Félipe Gruters, Rob |
| author_facet | de Jong, Wesley Aerts, Joeri Allard, Sabine Brander, Christian Buyze, Jozefien Florence, Eric van Gorp, Eric Vanham, Guido Leal, Lorna Mothe, Beatriz Thielemans, Kris Plana, Montse Garcia, Félipe Gruters, Rob |
| author_sort | de Jong, Wesley |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6909442 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69094422019-12-19 Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy de Jong, Wesley Aerts, Joeri Allard, Sabine Brander, Christian Buyze, Jozefien Florence, Eric van Gorp, Eric Vanham, Guido Leal, Lorna Mothe, Beatriz Thielemans, Kris Plana, Montse Garcia, Félipe Gruters, Rob Trials Correction BioMed Central 2019-12-13 /pmc/articles/PMC6909442/ /pubmed/31836017 http://dx.doi.org/10.1186/s13063-019-3940-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Correction de Jong, Wesley Aerts, Joeri Allard, Sabine Brander, Christian Buyze, Jozefien Florence, Eric van Gorp, Eric Vanham, Guido Leal, Lorna Mothe, Beatriz Thielemans, Kris Plana, Montse Garcia, Félipe Gruters, Rob Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy |
| title | Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy |
| title_full | Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy |
| title_fullStr | Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy |
| title_full_unstemmed | Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy |
| title_short | Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy |
| title_sort | correction to: ihivarna phase iia, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of ihivarna-01 in chronically hiv-infected patients under stable combined antiretroviral therapy |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909442/ https://www.ncbi.nlm.nih.gov/pubmed/31836017 http://dx.doi.org/10.1186/s13063-019-3940-0 |
| work_keys_str_mv | AT dejongwesley correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT aertsjoeri correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT allardsabine correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT branderchristian correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT buyzejozefien correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT florenceeric correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT vangorperic correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT vanhamguido correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT leallorna correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT mothebeatriz correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT thielemanskris correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT planamontse correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT garciafelipe correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT grutersrob correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy AT correctiontoihivarnaphaseiiaarandomizedplacebocontrolleddoubleblindedtrialtoevaluatethesafetyandimmunogenicityofihivarna01inchronicallyhivinfectedpatientsunderstablecombinedantiretroviraltherapy |